Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
One of the critical issues that should be addressed in the development of a BCG-based HIV vaccine is genetic plasmid stability. Therefore, to address this issue we have considered using integrative vectors and the auxotrophic mutant of BCG complemented with a plasmid carrying a wild-type complementi...
Main Authors: | Mahant, A, Saubi, N, Eto, Y, Guitart, N, Gatell, J, Hanke, T, Joseph, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Taylor and Francis
2017
|
Similar Items
-
Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
by: Aakash Mahant, et al.
Published: (2017-08-01) -
Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine
by: Saubi, N, et al.
Published: (2012) -
Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG
by: Saubi, N, et al.
Published: (2012) -
Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes.
by: Saubi, N, et al.
Published: (2011) -
Newborn Mice Vaccination with BCG.HIVA(222) plus MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes
by: Saubi, N, et al.
Published: (2011)